AR100680A1 - Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos - Google Patents

Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Info

Publication number
AR100680A1
AR100680A1 ARP150101706A ARP150101706A AR100680A1 AR 100680 A1 AR100680 A1 AR 100680A1 AR P150101706 A ARP150101706 A AR P150101706A AR P150101706 A ARP150101706 A AR P150101706A AR 100680 A1 AR100680 A1 AR 100680A1
Authority
AR
Argentina
Prior art keywords
molecules
antibodies
binding
same
molecule
Prior art date
Application number
ARP150101706A
Other languages
English (en)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR100680A1 publication Critical patent/AR100680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se dirige al mAb 1 y mAb 2 del anticuerpo anti-DR5, y a versiones humanizadas y quiméricas de tales anticuerpos. Adicionalmente a moléculas de unión de DR5 que comprenden fragmentos de tales moléculas, y a moléculas biespecíficas que incluyen diacuerpos, BiTEs, anticuerpos biespecíficos de protuberancias / agujeros, etc., que; comprenden: (i) tales fragmentos de unión de DR5 y (ii) un dominio capaz de unirse a un epítopo de una molécula presente sobre la superficie de una célula efectora. Reivindicación 31: La molécula de unión de DR-5 anti-humano de conformidad con cualquiera de las reivindicaciones 1 - 30, caracterizada porque la molécula se utiliza en el tratamiento de cáncer.
ARP150101706A 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos AR100680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562107786P 2015-01-26 2015-01-26

Publications (1)

Publication Number Publication Date
AR100680A1 true AR100680A1 (es) 2016-10-26

Family

ID=56544107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101706A AR100680A1 (es) 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Country Status (3)

Country Link
AR (1) AR100680A1 (es)
TW (1) TW201627322A (es)
WO (1) WO2016122701A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491234A3 (en) * 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
KR20190120783A (ko) * 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Gd2, nkg2d 및 cd16에 결합하는 단백질
CA3064714A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
CA3064743A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and ror1 or ror2
EP3630181A4 (en) * 2017-05-23 2021-03-17 Dragonfly Therapeutics, Inc. NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
KR20200037388A (ko) * 2017-08-16 2020-04-08 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
CA3080148A1 (en) * 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof
CN109836500A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957024A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
JP2021523140A (ja) * 2018-05-07 2021-09-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質
US20220226374A1 (en) * 2018-06-14 2022-07-21 2seventy bio, Inc Cd79b chimeric antigen receptors
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EP4139361A4 (en) * 2020-04-23 2024-05-15 Baylor College of Medicine Overcoming the tumor microenvironment for cell therapy by targeting myeloid derived suppressor cells through a trail-r2 specific receptor
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
KR20250093362A (ko) * 2022-10-20 2025-06-24 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 TRAIL 또는 FasL에 특이적으로 결합하는 항체 조합 및 이중특이 항체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
WO2012002723A2 (ko) * 2010-06-29 2012-01-05 성균관대학교산학협력단 투명 전도성막, 이의 제조 방법, 및 이를 이용한 투명전극 및 소자
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
WO2016122701A1 (en) 2016-08-04
TW201627322A (zh) 2016-08-01

Similar Documents

Publication Publication Date Title
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
CO2017012553A2 (es) Moléculas de unión a lag-3
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
CR20200539A (es) Receptores quiméricos de dll3 y métodos para su uso
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
EA201791270A1 (ru) Модифицированные april-связывающие антитела
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
HK1252675A1 (zh) 抗cd33抗体及其使用方法
MX382549B (es) Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
AR096445A1 (es) Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga
AR108451A1 (es) Anticuerpos anti-tenascina modificados y métodos de utilización

Legal Events

Date Code Title Description
FB Suspension of granting procedure